Pangaea Oncology (XMAD:PANG) Interest Expense: €-0.30 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:PANG Pangaea Oncology SA XMAD:PANG
61 GF Score
Price €1.50
GF Value €2.17
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Pangaea Oncology Interest Expense?

Pangaea Oncology XMAD:PANG 61 Interest Expense is €-0.30 Mil as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 61/100 and a GF Value™ of €2.17 (Possible Value Trap). The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Pangaea Oncology's interest expense for the six months ended in Dec. 2025 was € -0.20 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.30 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Pangaea Oncology's Operating Income for the six months ended in Dec. 2025 was € -1.99 Mil. Pangaea Oncology's Interest Expense for the six months ended in Dec. 2025 was € -0.20 Mil. Pangaea Oncology did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pangaea Oncology  (XMAD:PANG) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Pangaea Oncology's Interest Expense for the six months ended in Dec. 2025 was €-0.20 Mil. Its Operating Income for the six months ended in Dec. 2025 was €-1.99 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was €2.20 Mil.

Pangaea Oncology's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Pangaea Oncology did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Pangaea Oncology Interest Expense Historical Data

* Premium members only.

The historical data trend for Pangaea Oncology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pangaea Oncology Interest Expense Chart

Pangaea Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.25 -0.19 -0.13 -0.30 -0.30

Pangaea Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.12 -0.18 -0.10 -0.20
XMAD:PANG
61GF Score
Pangaea Oncology SA XMAD:PANG
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pangaea Oncology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.30 Mil mean?
Pangaea Oncology (XMAD:PANG) has a Interest Expense of €-0.30 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pangaea Oncology and its competitors.
Is Pangaea Oncology's Interest Expense too high?
Pangaea Oncology's current Interest Expense is €-0.30 Mil. Overall, Pangaea Oncology has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Interest Expense compare to TMO and DHR?
Pangaea Oncology's Interest Expense of €-0.30 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Diagnostics & Research company?
A good Interest Expense depends on the Medical Diagnostics & Research industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Pangaea Oncology and its competitors. Pangaea Oncology's current Interest Expense is €-0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.17, compared to a current price of €1.50 — trading 30.9% below its estimated fair value. The current Interest Expense is €-0.30 Mil. Pangaea Oncology's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Interest Expense is €-0.30 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?

Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued. The current stock price of €1.50 is trading 30.9% below its estimated GF Value™ of €2.17. GuruFocus considers Pangaea Oncology to be Possible Value Trap.

Key valuation signals for XMAD:PANG:

  • Interest Expense: €-0.30 Mil
  • GF Value™: €2.17 vs. price of €1.50 (30.9% below fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pangaea Oncology Business Description

Address Calle Sabino Arana, 5-19, Barcelona, ESP, 08028
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
61GF Score

Get the complete analysis for XMAD:PANG

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.50
Price
€2.17
GF Value